Roger Pomerantz - May 25, 2023 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role
Director
Signature
/s/ Daniel Chevallard, as Attorney-in-Fact
Stock symbol
VIRX
Transactions as of
May 25, 2023
Transactions value $
$0
Form type
4
Date filed
5/26/2023, 07:30 PM
Previous filing
Feb 28, 2023
Next filing
Jun 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIRX Common Stock Options Exercise $0 +9.04K +14.29% $0.00 72.3K May 25, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIRX Restricted Stock Units Options Exercise $0 -9.04K -11.11% $0.00 72.3K May 25, 2023 Common Stock 9.04K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
F2 One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.